article ban

title bar

References
Note:  Links to citations open in a new browser window.  To return to this page, just close the newly opened browser window by clicking on the X in the upper right hand corner of the window.

  1. Seymour RA. Oral and dental disorders. In: Davies DM, Ferner RE, DeGlanville H. eds., Davies's textbook of adverse drug reactions, 5th ed., London, Chapman & Hall Medical, 1998: 234-250.
  2. Regezi JA, Sciubba JJ. Oral pathology clinical pathologic corrections. 3rd ed., London, W.B. Saunders Company, 1999: 62-65, 158-159, 179, 181, 496.
  3. Jacobsen PL. Adverse drug reactions. In: Silverman S, Eversole LR, Truelove EL. Eds., Essentials of oral medicine, London, BC Decker Inc, 2001: 107-110.
  4. Moghadam BK, Drisko CL, Gier RE. Chlorhexidine mouthwash-induced fixed drug eruption; case report and review of the literature. Oral Surg Oral Med Oral Pathol. 1991 Apr;71(4):431-4. Review.
  5. Litt JZ. Drug eruption reference manual. London, The Parthenon Publishing Group, 2001: 274-421.
  6. Culhane NS, Hodle AD. Burning mouth syndrome after taking clonazepam. Ann Pharmacother. 2001 Jul-Aug;35(7-8):874-6.
  7. Vlasses PH, Rotmensch HH, Ferguson RK, et. al. Scalded mouth caused by angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1982 Jun 5;284(6330):1672-3. No abstract available.
  8. Savino L, Haushalter HM. Lisinopril-induced scalded mouth syndrome. Ann Pharmacother. 1992 Nov;26(11):1381-2.
  9. Brown RS, Krakow AM, Douglas T. Scalded mouth syndrome caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):665-7.
  10. Cawson RA, Binnie WH, Barrett AW, et. al. Oral disease, clinical and pathological correlations. 3rd ed., London, Mosby, 2001: 4.13, 11.15, 12.13, 12.14, 13.18, 13.19, 13.33.
  11. Dega H, Laporte JL, Frances C, et. al. Ginseng as a cause for Stevens-Johnson syndrome? Lancet. 1996 May 11;347(9011):1344. No abstract available.
  12. Lin AY, Baker BA. Verapamil-associated Stevens-Johnson syndrome. DICP. 1989 Dec;23(12):987-8.
  13. McAvoy BR. Letter: Mouth ulceration and slow-release potassium tablets. Br Med J. 1974 Oct 19;4(5937):164-5. No abstract available.
  14. Nordt SP. Tetracycline-induced oral mucosal ulcerations. Ann Pharmacother. 1996 May;30(5):547-8. No abstract available.
  15. Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers. Lancet. 1990 Jan 20;335(8682):164. No abstract available.
  16. Wittkowsky AK, Reddy R, Bardy GH. Oral mucosal ulceration from disopyramide. Ann Pharmacother. 1995 Dec;29(12):1299-1300. No abstract available.
  17. Newman MG, Takei HH, Carranza FA. Carranza’s clinical periodontology. London, W.B. Saunders Company, 2002:281-285.
  18. Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol. 2000 Sep-Oct;18(5):579-87. Review. No abstract available.
  19. Micromedex Healthcare Series, Drugdex, Drug Consults, Vol. 114, Disk B, 2002.
  20. Summitt JB, Robbins JW, Schwartz RS, et. al. Fundamentals of operative dentistry. 2nd ed., Chicago, Quintessence Publishing Co., 2001:402.
  21. Aschheim KW, Dale BG. Esthetic dentistry, a clinical approach to techniques and materials. 2nd ed., Philadelphia, Mosby, 2001:247-249.
  22. McKenna BE, Lamey PJ, Kennedy JG, et. al. Minocycline-induced staining of the adult permanent dentition: a review of the literature and report of a case. Dent Update. 1999 May;26(4):160-2. Review.
  23. Lindhe J, Karring T, Lang NP. Clinical periodontology and implant dentistry. 3rd ed., Copenhagen, Munksgoard, 1997: 346-349.
  24. Schincaglia GP, Forniti F, Cavallini R, et. al. Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med. 1992 Apr;21(4):181-5.
  25. Das SJ, Newman HN, Olsen I. Keratinocyte growth factor receptor is up-regulated in cyclosporine-A induced gingival hyperplasia. J Dent Res. 2002 Oct;81(10):683-7.
  26. Myrillas TT, Linden GJ, Marley JJ, et. al. Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. J Periodontol. 1999 Mar;70(3):294-300.
  27. Soory M, Suchak A. The effects of human mast-cell products and of phenytoin on androgen 5alpha-reductase expression in human gingival fibroblasts. Arch Oral Biol. 2001 Sep;46(9):847-55.
  28. Hassell TM, Burtner AP, McNeal D, et. al. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000. 1994 Oct;6:68-78. Review. No abstract available.
  29. Shimizu Y, Kataoka M, Seto H, et. al. Nifedipine induces gingival epithelial hyperplasia in rats through inhibition of apoptosis. J Periodontol. 2002 Aug;73(8):861-7.
  30. Fujimori Y, Maeda S, Saeki M, et. al. Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. Eur J Pharmacol. 2001 Mar 9;415(1):95-103.
  31. King GN, Fullinfaw R, Higgins TJ, et. al. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol. 1993 Apr;20(4):286-93.
  32. Dehpour AR, Abdollahi M, Alghasi H. Effects of lithium on rat parotid and submandibulary gland functions. Gen Pharmacol. 1995 Jul;26(4):851-4.
  33. Abdollahi M, Safarhamidi H. Protection by nitric oxide of morphine-induced inhibition of rat submandibular gland function. Pharmacol Res. 2002 Feb;45(2):87-92.
  34. Abdollahi M., Rahbar-Haghighat M, Soltaninejad K. Prevention by flumazenil of benzodiazepines-suppressed rat submandibular gland function. Indian Journal of Pharmacology 2002;34:164-171.
  35. Abdollahi M, Isazadeh Z. Inhibition of rat parotid and submandibular gland functions by ofloxacin, a fluoroquinolone antibiotic. Fundam Clin Pharmacol. 2001 Oct;15(5):307-11.
  36. Abdollahi M, Rahmat-Jirdeh N, Soltaninejad K. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Hum Exp Toxicol. 2001 Jan;20(1):28-33.
  37. Abdollahi M, Dehpour A, Shafayee F. L-arginine/nitric oxide pathway and interaction with lead acetate on rat submandibular gland function. Pharmacol Toxicol. 2000 Nov;87(5):198-203.
  38. Abdollahi M, Dehpour A, Kazemian P. Alteration by cadmium of rat submandibular gland secretory function and the role of the L-arginine/nitric oxide pathway. Pharmacol Res. 2000 Dec;42(6):591-7.
  39. Abdollahi M, Dehpour AR, Fooladgar M. Alteration of rat submandibulary gland secretion of protein, calcium and N-acetyl-beta-D-glucosaminidase activity by lead. Gen Pharmacol. 1997 Oct;29(4):675-80.
  40. Dehpour AR, Shirzad N, Ghafourifar P, et. al. Effects of cyclosporine A on the functions of submandibular and parotid glands of rats. Gen Pharmacol. 1996 Jul;27(5):887-90.
  41. Dehpour AR, Ghafourifar P, Massoudi S, et. al. On the relation of calcium channel blockers to rat parotid and submandibular glands function in vivo. Gen Pharmacol. 1995 May;26(3):619-22.
  42. Dehpour AR, Ghafourifar P, Madani F, et. al. Effects of vinca alkaloids on rat parotid and submandibular glands function in vivo. Gen Pharmacol. 1995 Mar;26(2):321-5.
  43. Dehpour AR, Abdollahi M. Effects of gentamicin on rat submandibulary gland functions. Gen Pharmacol. 1994 Dec;25(8):1719-22.
  44. Ghazi M, Dehpour AR, Abdollahi M, et. al. Lead intoxication in rats and its concentrations in blood and saliva. Toxic Subs Mech 1997;16: 327-385.
  45. Abdollahi M, Dehpour AR, Baharnouri G. Alteration by rubidium of rat submandibular secretion of protein and N-acetyl-?-D-glucosaminidase. Toxic Subs Mech 1998;17:121-131.
  46. Abdollahi M, Sharifzadeh M, Marzban H, et. al. Alteration by lead acetate of rats submandibular gland morphology and ultrastructure. Toxic Subs Mech 1999;18:139-148.
  47. Loria RC, Wedner HJ. Facial swelling secondary to inhaled bronchodilator abuse: catecholamine-induced sialadenosis. Ann Allergy. 1989 Apr;62(4):289-93.
  48. Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol. 2000 Sep-Oct;18(5):525-32. Review. No abstract available.
  49. Herrera JL, Lyons MF 2nd, Johnson LF. Saliva: its role in health and disease. J Clin Gastroenterol. 1988 Oct;10(5):569-78. Review.
  50. Mandel ID. A contemporary view of salivary research. Crit Rev Oral Biol Med. 1993;4(3-4):599-604.
  51. Knulst AC, Stengs CJ, Baart de la Faille H, et. al. Salivary gland swelling following naproxen therapy. Br J Dermatol. 1995 Oct;133(4):647-9.
  52. Anibarro B, Fontela JL. Sulfadiazine-induced sialadenitis. Ann Pharmacother. 1997 Jan;31(1):59-60.
  53. Ponte CD. A suspected case of trimipramine-induced salivary adenitis. Drug Intell Clin Pharm. 1982 Mar;16(3):248-9. No abstract available.
  54. Spolarich AE. Managing the side effects of medications. J Dent Hyg. 2000 Winter;74(1):57-69; quiz 71-2. Review.
  55. Braunwald E, Fauci AS, Kasper DL, et. al. Harrison’s principles of internal medicine. 15th ed., New York, McGraw-Hill, 2001:1974.
  56. White ID, Hoskin PJ, Hanks GW, et. al. Morphine and dryness of the mouth. BMJ. 1989 May 6;298(6682):1222-3. No abstract available.
  57. Hogan DJ, Strand LM, Lane PR. Isotretinoin therapy for acne: a population-based study. CMAJ. 1988 Jan 1;138(1):47-50.
  58. American Dental Association, 1995-2002.
  59. Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. Am J Med. 1986 Mar;80(3):471-6. Review.
  60. Catellani JE, Harvey S, Erickson SH, et. al. Effect of oral contraceptive cycle on dry socket (localized alveolar osteitis). J Am Dent Assoc. 1980 Nov;101(5):777-80.
  61. Grisius MM. Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):156-62. Review.
  62. Daniels TE, Wu AJ. Xerostomia-clinical evaluation and treatment in general practice. J Calif Dent Assoc 2000;28(12):933-941.
  63. Smith RG, Burtner AP. Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist. 1994 May-Jun;14(3):96-102. Review.
  64. Moore PA, Gage TW, Hersh EV, et. al. Adverse drug interactions in dental practice. Professional and educational implications. J Am Dent Assoc. 1999 Jan;130(1):47-54.
    65.

 
 
previous page next page
Page 21 of 22
Citation Number: Vol. 4, No. 1, Page 030